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Abstract
Background: While there is currently no cure for multiple sclerosis (MS), treatment with biologic disease-
modifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the 
regulatory change in the distribution system of bDMDs, limited their administration through the designated 
pharmacies of the National Organization for Healthcare Services Provision (EOPYY) or the National Health 
System (ESY) hospitals, thus potentially impacting access to MS treatment. In this context, the aim of this paper 
was to assess the barriers to bDMDs, by recording MS patients’ experiences.
Methods: A survey research was conducted between January and February 2014 in Athens and 5 other major 
Greek cities with the methods of personal and telephone interview. A structured questionnaire was used to elicit 
socio-economic and medical information, information related to obstacles in accessing bDMDs and medical 
treatment, from MS patients that visited EOPYY pharmacies during the study period.
Results: During the last year 69% of 179 participants reported that the distribution system of bDMDs has 
improved. Thirteen percent of participants encountered problems in accessing their medication, and 16.9% of 
participants in accessing their physician, with the obstacles being more pronounced for non-Athens residents. 
Frequent obstacles to bDMDs were the distance from EOPYY pharmacies and difficulties in obtaining a diagnosis 
from an EOPYY/ESY physician, while obstacles to medical care were delays in appointment booking and travel 
difficulties. 
Conclusion: Even though the major weaknesses of the distribution system of bDMDs have improved, further 
amelioration of the system could be achieved through the home delivery of medicines to patients living in remote 
areas, and through the development of a national MS registry.
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Implications for policy makers
• Distribution of biologic disease-modifying drugs (bDMDs) for multiple sclerosis (MS) through the National Organization for Healthcare 
Services Provision (EOPYY) pharmacies has improved during the last year.
• Despite the improvement in the operation of the distribution system, one in 8 patients continues to encounter barriers in accessing MS 
medication.
• There are inequalities in accessing care, with patients living outside Attica encountering more obstacles compared to Attica residents.
• A potential solution in tackling the existing inequalities in accessing bDMDs is the home delivery of medicines to MS patients living in remote 
areas with poor means of transportation. 
• The development of a national MS registry could further facilitate the distribution process of bDMDs, ensuring patient eligibility and thus 
enhancing access to care and the health status of MS patients.
Implications for public
The present study has been conducted in an effort to highlight the obstacles in accessing treatment for multiple sclerosis (MS) with biologic 
disease-modifying drugs (bDMDs) in Greece in the era of economic crisis. The economic downturn and the need for fiscal consolidation have 
led to the implementation of a number of cost-containment measures in the Greek pharmaceutical market, such as the recent change in the 
distribution system of costly medicine, including bDMDs for MS. Thus, during the last two years, Greek MS patients have abruptly moved from a 
status of unrestricted and fairly easy access to bDMDs to a complex distribution system which has limited their access to effective treatment. In this 
context, the purpose of this study is to increase awareness regarding the obstacles encountered by Greek MS patients in accessing their treatment, 
and to propose measures that could potentially improve the situation.
Key Messages 
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Background
The dimensions of quality in health according to Maxwell1 
are accessibility, equality, responsiveness to the needs of 
patients and the community, social acceptance, efficiency, and 
effectiveness. People who suffer from chronic diseases such as 
multiple sclerosis (MS) use health services more frequently 
than the general population. This brings patients face to face 
with the potential weaknesses of the health system that affect 
quality of healthcare, impeding accessibility as well as the 
smooth operation of these services.2,3 
Patients with MS need to have direct access to pharmaceutical 
treatment that best meets their needs.4 While there is 
currently no cure available for MS, there are pharmaceutical 
interventions, ie, biologic disease-modifying drugs (bDMDs, 
eg, beta interferon-1a, beta interferon-1b, glatiramer acetate, 
natalizumab, fingolimod, mitoxantrone), that can significantly 
reduce the impact of the condition on the lives of patients, by 
treating relapses and stabilizing the health status of patients,4-6 
thus improving their quality of life and leading to reduced loss 
of productivity, and reduced direct and indirect costs. In this 
respect, in order to assess the level of access to effective MS 
treatment, the accessibility of patients to bDMDs is usually 
evaluated by the academic community.7-9
In Greece, MS treatment with bDMDs has been traditionally 
fully reimbursed by social insurance according to legislation, 
while according to the 2013 MS Barometer report, 
approximately 70% of Greek MS patients are being treated 
with bDMDs, which is one of the highest percentages in 
Europe.9 In the context of Greece’s economic adjustment 
programme, a number of policy measures and regulatory 
changes have been implemented in the Greek pharmaceutical 
sector since 2010, in an effort to rationalize public 
expenditure and control excess prescribing. Thus, the latest 
regulatory change in the distribution system of high-cost, 
fully reimbursed, medicines (ie, medicines defined by Law 
3816/2010), including bDMDs for MS, has limited access to 
high-cost pharmaceuticals, by allowing their administration 
only through the publicly-owned, designated pharmacies of 
the National Organization for Healthcare Provision (EOPYY) 
or the National Health System (ESY) hospitals (medicines 
administered by hospitals if: (a) the medicine is administered 
by intravenous infusion and therefore is only for hospital 
use, or (b) the use of the medicine must start under hospital 
monitoring and can be continued outside the hospital but 
under hospital surveillance, according to its packaging 
information –“blue box”), and only when their prescription 
is accompanied by an appropriate medical diagnosis issued by 
a hospital physician. The aim of this measure was to contain 
public pharmaceutical costs and to ensure that high-cost 
medicines such as bDMDs are prescribed according to official 
treatment guidelines and protocols.10
In the light of this regulatory change, a recent study by 
Souliotis et al,11 ie, HOPE I (Health Outcomes Patient 
Environment I) study, assessed access to high-cost medicine 
for the treatment for rheumatoid arthritis (disease-modifying 
antirheumatic drugs, DMARDs) in Greece, concluding that 
patients are facing increased barriers to access timely and 
effective treatment under the new distribution system. In this 
context, the objective of the present study, ie, HOPE II, was 
to assess the operation of the high-cost medicine distribution 
system one year later, and in another disease area, ie, in MS, 
based on the experiences of patients. Specifically, this study 
aims to assess the access of MS patients primarily to bDMDs 
and secondarily to medical care following the implementation 
of the new distribution system, drawing on the different 
obstacles presented to patients and on their correlation to 
the socio-economic characteristics of patients. Even though 
the main objective of the paper was to evaluate the access to 
bDMDs for MS patients, data on access to MS medical care 
was also collected in order to identify potential correlations 
between the obstacles encountered in the 2 types of care. MS 
patients need to see their doctor in order to get a prescription 
for a bDMD, therefore the frequency and the different 
obstacles related to medical visits may influence access to 
bDMDs. Moreover, by collecting data on both medical and 
pharmaceutical MS treatment, we attempted to review access 
to MS care as a whole in the era of economic crisis in Greece.
Methods
For the HOPE II study a survey research was conducted 
between January and February 2014 in Athens (Attica 
prefecture) and other urban areas in Greece. Data for the 
study were collected with personal and telephone interviews 
by filling out a questionnaire, in 7 pharmacies of EOPYY, 
located in Athens (2 pharmacies) and other major cities of 
the Greek mainland (4 pharmacies in Ioannina, Lamia, 
Thessaloniki, Alexandroupoli) and the islands (1 pharmacy in 
Herakleion, Crete). The target population was defined as the 
finite population subset corresponding to those MS patients 
who, during the study period, visited EOPYY pharmacies in 
order to obtain their MS pharmaceutical prescription. Patients 
with 12 months of treatment at least before the starting time 
of the survey were included in the sample. 
The purpose of the questionnaire was to examine MS patients’ 
attitude towards the conditions of medical and pharmaceutical 
care for their illness. The questionnaire was formulated in 
such a way as to safeguard the anonymity of respondents. The 
respondents were kindly requested to respond to all questions 
with the utmost accuracy. The questionnaire consisted of 4 
tiers of questions including multiple-choice or open-ended 
questions to collect information on: (a) Demographic and 
financial characteristics of MS patients, ie, age, gender, 
place of birth, place of residence, education level, level of 
monthly income, source of income, type of profession, self-
assessment of economic situation, type of health insurance; 
(b) Clinical and medical parameters related to the history and 
management of MS, ie, year of initial diagnosis of disease, 
type of treating physician, frequency of medical visits, mode 
of administration of treatment; (c) The frequency and type 
of difficulties/problems experienced by the participants in 
accessing pharmaceutical and medical MS care during the 
last year (eg, “Have you encountered obstacles in accessing 
MS pharmaceutical care during the last 12 months?,” “If 
yes, this is due to: a. Distance from EOPYY pharmacies, b. 
Difficulties in prescription process due to limited accessibility 
to physician’s clinic, c. Difficulties in obtaining the required 
medical diagnosis by a hospital physician” etc.) and (d) The 
patients’ opinion about the quality of pharmaceutical care 
provision with regards to the distribution of MS medication 
through the EOPYY pharmacies, measured on a 5-point Likert 
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scale (ie, “Overall, do you think that the process of obtaining 
your MS medication through the EOPYY pharmacies has 
improved during the last 12 months?”). In the 2 multiple-
choice questions regarding the type of obstacles experienced 
in accessing pharmaceutical and medical care, participants 
could provide more than one answer, ie, “You may choose 
more than one obstacles.”
The prevalence of MS in Greece is estimated at 10 000-12 000 
based on data from the Greek MS Patient Association. For 
the purposes of the study and in accordance with its cost 
and time limitations, a sample of 2% of the population was 
targeted, ie, approximately 200 questionnaires. Because of the 
selected method of personal interview, a high response rate 
was reached, namely, 180 out of the 200 questionnaires. From 
these questionnaires, 179 fully completed questionnaires were 
suitable for statistical processing. Statistical analysis included 
the calculation of empirical frequency and relative frequency 
distributions. Population parameters were estimated using 
measures of location (arithmetic mean) and dispersion 
(standard deviation). Differences between populations were 
tested with t tests. The level of statistical significance was 
set at 1%.
Results
The study population consisted of 179 MS patients who 
visited one of the participating EOPYY pharmacies, either in 
Athens (51%, n = 91) or in other 5 major Greek cities (49%, 
n = 88, ie, Herakleion, n = 25; Ioannina, n = 23; Lamia, n = 18; 
Thessaloniki, n = 13; Alexandroupoli, n = 9) during the study 
period. The majority of the study participants belonged to 
the 36-50 age-group, while 63% of them were women and 
37% were men, with a mean time since MS diagnosis of 8.4 
years (standard deviation [SD ] = 6.4) and 7.7 years (SD = 5.0) 
respectively. Most patients had received secondary education 
and reported a monthly income of up to €1000, while 92% 
of patients did not have private insurance. The detailed 
demographic and socio-economic characteristics of the 
patient population are presented in Table 1.
Access to Multiple Sclerosis Medical Treatment
Access to MS medical treatment was assessed through the 
study questionnaire in order to identify potential factors/
obstacles that could further impact on access to bDMDs for 
MS patients, and to assess access to MS care as a whole. 
Based on the study results, 60.2% of MS patients reported 
visiting their treating physician once every three months, 
while 16.5% of patients visited their doctor once a month over 
the previous year (Figure 1). Most patients (81%) preferred 
visiting physicians at ESY hospitals, while the rest opted 
for private physicians (contracted or non-contracted with 
EOPYY), or physicians at EOPYY health centers. During 
their physician visit, 88% of patients were prescribed MS 
medication which did not require short-term hospitalization.
One in 6 respondents, ie, 16.9% of all patients, answered 
positively to the question “Have you encountered obstacles in 
accessing MS medical care during the last 12 months?,” while 
this percentage was higher among those who were prescribed 
medication that did not require short-term hospitalization, ie, 
17.7% (versus 9.5% among patients whose medication require 
short-term hospitalization). The most frequently reported 
Table 1. Patient Characteristics
Demographic, and Socio-economic 
Characteristics 
No. of Patients %
Total 179 100.0
Gender
Men 67 37.3
Women 112 62.7
Age (years)
≤25 10 5.7
26-35 37 20.3
36-50 95 53.1
51-65 34 19.2
≥66 3 1.7
Education 
Compulsory education 22 12.1
Secondary education 80 44.5
Technological education 21 11.6
Higher education 44 24.9
Postgraduate education 12 6.9
Monthly income
≤€500 33 18.1
€501-€1000 86 48.1
€1001-€1500 50 28.1
€1501-€2000 2 1.3
€2001-€2500 5 2.5
>€2500 3 1.9
Self-assessment of economic status
Very good 2 1.3
Good 24 13.3
Fair 87 48.7
Bad 53 29.7
Very bad 13 7.0
Private insurance
Yes 15 8.3
No 164 91.7
Place of residence
Prefecture of Attica 88 49.2
Outside of prefecture of Attica 91 50.8
Figure 1. Distribution of Patients According to the Frequency of 
Physicians’ Visits.
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cause of reduced accessibility to the MS physician was the 
delay in scheduling an appointment with the doctor, followed 
by travel difficulties and the inability to pay a non-contracted 
private physician (Table 2).
According to the analysis of the study results, the level 
of monthly income was shown to be associated with the 
frequency of scheduled medical visits, as the percentage of 
patients delaying their medical visit appeared to be higher 
among those with a monthly income less than €500, ie, 13.8%, 
compared to the respective percentage reported among 
patients with an income higher than €500, ie, 7%, yet their 
difference was not significant (P = .3). Low-income (≤€500) 
MS patients also reported relatively high inability to pay for a 
non-contracted private physician (10.4% versus 3.1%; P = .2), 
as well as more difficulties due to the distance from the 
physician’s clinic (3.5% versus 1.6%; P = .5). As further analysis 
of the distribution of patients with respect to their income 
and place of residence showed that the percentage of Athens 
residents with a monthly income less than €500 was 5.8%, 
compared to the significantly higher respective percentage of 
32.4% (P < .001) among non-Athens residents, we can deduce 
that patients residing outside Athens have a higher risk of 
experiencing a barrier to access their MS treatment. 
Access to Multiple Sclerosis Pharmaceutical Treatment
With regards to accessing MS treatment with bDMDs, 
approximately one in eight respondents, ie, 13.3% of all 
patients, answered positively to the question “Have you 
encountered obstacles in accessing MS pharmaceutical care 
during the last 12 months?,” while, again, this percentage was 
higher among those who were prescribed medication that did 
not require short-term hospitalization, ie, 14% versus (the non-
statistically lower) 4.8% among patients whose medication 
require short-term hospitalization (P = .1). In this respect, the 
reported barriers were related to the distribution channels 
of MS medication, and also to the prescribing process. In 
particular, the most frequently reported obstacle encountered 
in accessing bDMDs was the long distance required to reach 
an EOPYY pharmacy, followed by the reduced accessibility 
of patients to their treating physician, and the difficulties 
Table 2. Commonly Reported Barriers to Accessing MS Medical 
Treatment
Commonly Reported Obstacles  No. of Cases %
Delay in scheduling an appointment with a 
physician working at an NHS hospital or at 
EOPYY’s health centers 
15 40.6
Difficulties of travel to and from the clinic due to 
health reasons or lack of means of transportation
9 24.3
Inability to pay a non-contracted private 
physician
8 21.6
Distance from physician’s clinic 4 10.8
Difficulty in scheduling an appointment with a 
contracted private physician
1 2.7
Total 37 100.0
Abbreviations: MS, multiple sclerosis; NHS, National Health Service; EOPYY, 
National Organization for Healthcare Services Provision.
Note: This table presents the frequency and relative frequency distribution 
of barriers experienced by patients who gave a positive answer to the 
question: “Have you experienced obstacles in accessing MS medical care 
during the last 12 months?”
Table 3. Commonly Reported Barriers to Accessing MS 
Pharmaceutical Treatment
Commonly Reported Obstacles No. of Cases %
Distance from EOPYY pharmacies 9 28
Difficulties in prescription process due to limited 
accessibility to physician’s clinic
5 15
Difficulties in obtaining the required medical 
diagnosis by a NHS hospital physician
5 15
Difficulties related to the availability or the 
administration of MS medication in ESY hospitals
3 9
Non-availability of medication in ESY hospitals 3 9
Distance from ESY hospitals 2 6
Distance from private pharmacies 2 6
Pharmacists’ strikes 2 6
Difficulties in the administration/non-availability 
of medication in private pharmacies
1 3
Difficulties in the administration/non-availability 
of medication in EOPYY pharmacies 
1 3
Total 33 100
Abbreviations: MS, multiple sclerosis; NHS, National Health Service; EOPYY, 
National Organization for Healthcare Services Provision; ESY, National 
Health System.
Note: This table presents the frequency and relative frequency distribution 
of barriers experienced by patients who gave a positive answer to the 
question: “Have you experienced obstacles in accessing MS medical care 
during the last 12 months?”
in obtaining the required medical diagnosis by a hospital 
physician (Table 3).
The barriers to accessing bDMDs were shown to be statistically 
significantly more pronounced for non-Attica residents who 
live in urban centers of the Greek mainland, as the mean 
number of obstacles reported by them was 2.3 compared to 
0.6 for Attica residents (P = .0).
Almost 98% of MS patients who experienced obstacles in 
accessing their medication, were eventually able to receive 
fully reimbursed bDMDs through the designated distribution 
channels (ie, EOPYY pharmacies or ESY hospitals), and 
therefore did not have to either pay-out-of-pocket or make 
any changes in their therapeutic regimen (eg, did not have 
to switch to another – non-bDMD – MS medicine that is 
available in retail pharmacies). In addition, 9% of these 
patients missed or delayed treatment, which resulted in a 
deteriorated health status for 5% of them.
Moreover, with regards to the attitude of patients towards 
the distribution of MS medication through the EOPYY 
pharmacies, the study participants were asked their personal 
opinion on whether the distribution process has improved 
during the last twelve months. Thus, 69% of MS patients 
answered that the distribution process has indeed improved 
or improved a lot (Figure 2), while this percentage was higher 
among non-Attica residents, ie, 71% (versus 66.7 % among 
Attica residents; P = .5).
Further analysis of the data by geographic region and by type 
of administration of treatment (medication requiring short-
term hospitalization or no hospitalization) showed that the 
process improved or substantially improved particularly 
outside Attica, and especially among patients who receive 
treatment that does not require short-term hospitalization 
(73.6%) (Figure 3). These patients need to access EOPYY 
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pharmacies to get their medication, as compared to patients 
who receive treatment that requires hospitalization, in which 
case the treatment is provided by the hospital.
Discussion
A number of studies have shown that there is wide and 
inconsistent variation in the access of MS patients to bDMDs 
across Europe, showing that there are still significant 
inequalities in access to effective MS care.6-8 Kobelt and 
Kasteng6 estimated that the proportion of MS patients on 
DMDs varied between approximately 6% and 83% among 
European countries. Wilsdon et al7 found a range of 13% and 
69% in a more recent study, while the 2013 MS Barometer 
reported a range of 11% and 70%.8
A number of factors may explain the differences in the use 
of bDMDs, but the most important determinants of access 
to bDMD treatment are, on one hand, issues related to their 
reimbursement process and differences in affordability across 
European economies, and on the other hand issues related to 
Figure 2. Patients’ Answer to the Question: “Overall, Do You Think 
That the Process of Obtaining Your MS Medication Through the 
EOPYY Pharmacies Has Improved During the Last 12 Months?”
Figure 3. Patients Attitude Towards the Improvement of the Distribution System of MS medication, during the Last 12 Months, by Place of 
Residence and Type of Pharmaceutical Treatmenta.
medical practice, ie, differences pertaining the diagnosis and 
management process of the disease.4,6,7
In Greece, even though the overall score for access to treatment 
and therapies in general is below the European average 
(especially in terms of psychological care and rehabilitation 
services), access to bDMDs has been particularly high in the 
past years.8 Nevertheless, during the Greek economic crisis, 
access to fully reimbursed, high-cost medicine for serious, 
costly illnesses such as, rheumatoid arthritis (RA) and MS has 
been restricted, by distributing these medicines exclusively 
through the pharmacies of EOPYY or the pharmacies of ESY 
hospitals, and not through private pharmacies. This measure 
was implemented primarily to reduce public spending for 
high-cost medicines, as in this way, the State purchased 
them at discounted, hospital price, without incurring the 
extra cost resulting from the reimbursement of medicines at 
pharmacy, retail price. In addition, the measure aimed at a 
higher control of the eligibility of patients and the compliance 
to clinical guidelines, by applying additional requirements in 
the distribution process, ie, a medical diagnosis issued by an 
EOPYY/ESY doctor that needs to be submitted together with 
the prescription, in order to obtain the medicine.
However, the implementation of the new distribution system 
did not come without problems. The complexity of the system 
stemming from the increased administrative barriers and the 
limited points of distribution, combined with the medicine 
shortages that occurred in ESY hospitals due to the instability 
of the Greek pharmaceutical market during the first months 
of the system’s operation, severely affected access to medicines, 
especially for patients residing outside the prefecture of 
Attica. This resulted in anxiety, confusion and discomfort 
for patients, who often had to travel long distances to ensure 
access to their medicines. As shown in the HOPE I study by 
Souliotis et al,11 one in 2 patients with RA reported problems 
in accessing biologic DMARDs during 2012 through the 
new system, which they attributed to the long distance from 
EOPYY pharmacies, difficulties in accessing a prescribing 
a Treatment requiring or not short-term hospitalization.
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doctor and to the non-availability or difficulty of finding their 
medication at an ESY hospital or EOPYY pharmacy.
The present, HOPE II study, which was conducted one 
year after the HOPE I study and in a different disease area, 
showed that according to the majority of respondents, there 
has been improvement and streamlining in the operation 
of the distribution system. This is also confirmed by the 
fact that, as mentioned before, 9% of the study population 
reported delaying or missing treatment which subsequently 
led to the deterioration of health status for 5% of them. 
These percentages are substantially lower compared to the 
corresponding percentages reported in HOPE I11 one year 
earlier where 18% of patients with RA reported delay or loss of 
treatment, leading to the deterioration of health status for 22% 
of them. The improvement in accessing high-cost medicine 
can be attributed to the operation of additional points of 
administration in the distribution system, ie, additional 
EOPYY pharmacies, especially outside Attica as well as to 
the relative stabilization of the Greek pharmaceutical market, 
during the last year. 
At this point, it should be stressed, however, that the two 
studies looked at different patient populations in different 
points in time, and therefore differences in results could 
also be related to the differences in clinical practice and 
prescribing habits of attending physicians in Greece. Based 
on the literature, overall uptake of bDMDs for MS is higher 
in Europe, compared to the uptake of DMARDs for RA, 
despite the fact that the effectiveness of biologics in the latter 
disease area is well-documented.7 This could be because 
the prevalence of MS is lower compared to that of RA, and 
therefore the budget impact of the prescription of bDMDs 
among MS patients is more limited compared to that of the 
prescription of DMARDs among RA patients, thus resulting 
in better, less restricted access to innovative medications for 
MS patients on affordability grounds.7,12-15
Yet, despite the improvement in the operation of the 
distribution system, problems still exist, with one in eight MS 
patients reporting barriers in accessing bDMDs. Similarly 
to the previous HOPE I study,11 the distance from EOPYY 
pharmacies continued to present a major obstacle for patients, 
while other obstacles were related to the difficulties in 
obtaining the required medical diagnosis by an ESY/EOPYY 
physician, and to the reduced accessibility of patients to their 
treating physician. These barriers could be overcome through 
the development of an MS national registry which would 
standardize the distribution process (and home delivery) and 
assure comprehensive, and faster patient access to treatment. 
A registry could help EOPYY to identify, early on, the number 
of patients that need treatment at a given period in time, as 
well as the frequency of their visits to doctors and pharmacies, 
and therefore speed up patients’ access to their medication 
and avoid shortages. 
Conclusion
The current distribution system for high-cost medicines is 
a potentially effective cost-containment measure applied 
in the context of fiscal consolidation in Greece. Based on 
the findings of the present study, even though the major 
weaknesses of the system seem to have improved to a certain 
extent during the last year, there is still room for improvement. 
To further ameliorate the operation of the distribution system 
and to remove the existing barriers in the short-term, a 
potential solution could be the home delivery of medicines 
to MS patients, especially for patients living in remote areas 
with poor means of transportation, tackling in this way the 
existing inequalities in accessing medication. Moreover, in the 
medium – term, the development of a national MS registry 
could be used to further facilitate the distribution process of 
high-cost medicine, ensuring patient eligibility and medicine 
adequacy, and thus enhancing access to care and the health 
status of MS patients. 
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